Tolvaptan, the Novel Medicine to Optimize Serum Sodium Concentrations in Patients with Heart Failure

2013 ◽  
Vol 19 (10) ◽  
pp. S160
Author(s):  
Masatake Kobayashi ◽  
Kunihiko Teraoka ◽  
Yoichi Iwasaki ◽  
Yuto Kumai ◽  
Mamoru Aiga ◽  
...  
Author(s):  
Abu Ghosh Z ◽  
◽  
Beeri R ◽  
Falah B ◽  
Pertz A ◽  
...  

Oncology patients with Heart Failure (HF) and severe Mitral Regurgitation (MR) are often considered to have a prohibitive risk for surgical mitral valve repair/replacement. We describe a patient with active multiple myeloma and significant HF and MR who was treated with MitraClip, which improved symptoms and allowed delivery of optimal oncological treatment.


2013 ◽  
Vol 34 (6) ◽  
pp. 1463-1468 ◽  
Author(s):  
Rebecca B. Regen ◽  
Ashley Gonzalez ◽  
Kasey Zawodniak ◽  
David Leonard ◽  
Raymond Quigley ◽  
...  

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 175
Author(s):  
Radu-Stefan Miftode ◽  
Antoniu Octavian Petriș ◽  
Viviana Onofrei Aursulesei ◽  
Corina Cianga ◽  
Irina-Iuliana Costache ◽  
...  

The increasing incidence of coronavirus disease 19 (COVID-19) and its polymorphic clinical manifestations due to local and systemic inflammation represent a high burden for many public health systems. Multiple evidence revealed the interdependence between the presence of cardiovascular comorbidities and a severe course of COVID-19, with heart failure (HF) being incriminated as an independent predictor of mortality. Suppression of tumorigenicity-2 ST2 has emerged as one of the most promising biomarkers in assessing the evolution and prognosis of patients with HF. The uniqueness of ST2 is determined by its structural particularities. Its transmembrane isoform exerts cardioprotective effects, while the soluble isoform (sST2), which is detectable in serum, is associated with myocardial fibrosis and poor outcome in patients with HF. Some recent data also suggested the potential role of sST2 as a marker of inflammation, while other studies highlighted it as a valuable prognostic factor in patients with COVID-19. In this review, we summarized the pathways by which sST2 is related to myocardial injury and its connection to the severity of inflammation in patients with COVID-19. Also, we reviewed possible perspectives of using it as a dual cardio-inflammatory biomarker, for both early diagnosis, risk stratification and prognosis assessment of patients with concomitant HF and COVID-19.


2021 ◽  
Vol 20 (Supplement_1) ◽  
Author(s):  
AM Trenta ◽  
D Ausili ◽  
R Caruso ◽  
M Moro ◽  
T Nania ◽  
...  

Abstract Funding Acknowledgements Type of funding sources: None. Background The COVID-19 outbreak has presented significant challenges for healthcare systems worldwide, which are responsible for guaranteeing access to care for all patients and limiting the spread of the virus. The necessary changes in the healthcare systems have deeply impacted not only people affected by the novel coronavirus, but also those with chronic conditions, such as heart failure. Since the beginning of the pandemic, a reduction of routine visits and use of emergency services by patients with heart failure has been observed, and these patients have tended to visit the hospital only when their symptoms were severe. The consequences of the COVID-19 pandemic on heart failure patients’ lives have not yet been investigated. Purpose To explore the lived experiences of patients with heart failure during the COVID-19 pandemic. Methods A qualitative investigation based on interpretative phenomenological analysis was conducted. Fourteen patients with heart failure (12 males and 2 females with a median age of 68 years) completed in-depth, semi-structured interviews. Triangulation, journaling and member checking were used to improve the rigour of the study. Results Three themes describing the lived experience of patients were identified: "being vulnerable", "hanging in the balance", and "coping strategies". Patients reported feeling particularly vulnerable to the novel coronavirus due to their clinical conditions, and therefore they experienced fear and anxiety. Changes in the healthcare systems due to the COVID-19 pandemic created a sense of uncertainty that patients described as a feeling of hanging in the balance. However, despite these relevant difficulties, heart failure patients have managed to deal with the situation using various coping strategies, such as acceptance, recreational activities, family reorganization, and use of technology. Conclusions The COVID-19 outbreak deeply affected the lives of patients with heart failure, and our results highlight the relevant difficulties they have faced. We point out that there is a great need for targeted interventions, and these could be developed taking into consideration the coping strategies described in the study.


2011 ◽  
Vol 68 (4) ◽  
pp. 328-333 ◽  
Author(s):  
Philip L. Cyr ◽  
Katherine A. Slawsky ◽  
Natalia Olchanski ◽  
Holly B. Krasa ◽  
Thomas F. Goss ◽  
...  

2003 ◽  
Vol 308 (3) ◽  
pp. 480-485 ◽  
Author(s):  
Gábor Földes ◽  
Ferenc Horkay ◽  
István Szokodi ◽  
Olli Vuolteenaho ◽  
Mika Ilves ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document